trimethyloxamine has been researched along with Myocardial Infarction in 20 studies
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure
trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riboflavin is a cofactor in TMAO synthesis." | 5.56 | Circulating trimethyllysine and risk of acute myocardial infarction in patients with suspected stable coronary heart disease. ( Berge, RK; Bjørnestad, EØ; Dhar, I; Løland, K; Nilsen, DWT; Nordrehaug, JE; Nygaard, E; Nygård, O; Olset, H; Pedersen, EKR; Svardal, A; Svingen, GFT; Tell, GS; Ueland, PM, 2020) |
| "The relationship between sodium glucose co-transporter 2 inhibitors (SGLT2i) and trimethylamine N-oxide (TMAO) following acute myocardial infarction (AMI) is not yet explored." | 4.31 | Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial. ( Aziz, F; Curcic, P; Hermann, M; Kolesnik, E; Mangge, H; Meinitzer, A; Pferschy, PN; Sourij, H; Tripolt, NJ; von Lewinski, D, 2023) |
| "Trimethylamine N-oxide (TMAO) and phenylacetylglutamine (PAGln) are associated with acute myocardial infarction (AMI) and type 2 diabetes mellitus (T2DM)." | 4.12 | Analysis of two intestinal bacterial metabolites (trimethylamine N-oxide and phenylacetylglutamine) in human serum samples of patients with T2DM and AMI using a liquid chromatography tandem mass spectrometry method. ( Cui, J; Ma, X; Qiu, L; Tang, Y; Yu, S; Zhang, L; Zou, Y, 2022) |
| " Dose-response meta-analysis revealed that the relative risk (RR) for all-cause mortality increased by 7." | 2.55 | Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. ( Esposito, G; Franzone, A; Gargiulo, G; Giugliano, G; Perrino, C; Sannino, A; Schiattarella, GG; Toscano, E; Trimarco, B, 2017) |
| "Riboflavin is a cofactor in TMAO synthesis." | 1.56 | Circulating trimethyllysine and risk of acute myocardial infarction in patients with suspected stable coronary heart disease. ( Berge, RK; Bjørnestad, EØ; Dhar, I; Løland, K; Nilsen, DWT; Nordrehaug, JE; Nygaard, E; Nygård, O; Olset, H; Pedersen, EKR; Svardal, A; Svingen, GFT; Tell, GS; Ueland, PM, 2020) |
| "In individuals with type 1 diabetes, higher concentrations of plasma TMAO were associated with mortality, CVD events, and poor renal outcome, independent of conventional risk factors." | 1.51 | Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. ( Ahluwalia, TS; Hansen, TW; Hazen, SL; Jorsal, A; Parving, HH; Pedersen, O; Rossing, P; Tarnow, L; Theilade, S; Tofte, N; Wang, Z; Winther, SA; Øllgaard, JC, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 8 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, N | 1 |
| Zhou, J | 1 |
| Wang, Y | 1 |
| Chen, R | 1 |
| Li, J | 1 |
| Zhao, X | 1 |
| Zhou, P | 1 |
| Liu, C | 1 |
| Song, L | 1 |
| Liao, Z | 1 |
| Wang, X | 1 |
| Yan, S | 1 |
| Zhao, H | 1 |
| Yan, H | 1 |
| Yoshida, Y | 2 |
| Shimizu, I | 1 |
| Shimada, A | 1 |
| Nakahara, K | 1 |
| Yanagisawa, S | 1 |
| Kubo, M | 1 |
| Fukuda, S | 1 |
| Ishii, C | 1 |
| Yamamoto, H | 1 |
| Ishikawa, T | 1 |
| Kano, K | 1 |
| Aoki, J | 1 |
| Katsuumi, G | 1 |
| Suda, M | 1 |
| Ozaki, K | 1 |
| Okuda, S | 1 |
| Ohta, S | 1 |
| Okamoto, S | 1 |
| Minokoshi, Y | 1 |
| Oda, K | 1 |
| Sasaoka, T | 1 |
| Abe, M | 1 |
| Sakimura, K | 1 |
| Kubota, Y | 1 |
| Yoshimura, N | 1 |
| Kajimura, S | 1 |
| Zuriaga, M | 1 |
| Walsh, K | 1 |
| Soga, T | 1 |
| Minamino, T | 1 |
| Tang, Y | 1 |
| Zou, Y | 2 |
| Cui, J | 1 |
| Ma, X | 1 |
| Zhang, L | 1 |
| Yu, S | 1 |
| Qiu, L | 1 |
| Aziz, F | 1 |
| Tripolt, NJ | 1 |
| Pferschy, PN | 1 |
| Kolesnik, E | 1 |
| Mangge, H | 1 |
| Curcic, P | 1 |
| Hermann, M | 1 |
| Meinitzer, A | 1 |
| von Lewinski, D | 1 |
| Sourij, H | 1 |
| Zhou, X | 1 |
| Jin, M | 1 |
| Liu, L | 1 |
| Yu, Z | 1 |
| Lu, X | 1 |
| Zhang, H | 1 |
| Bjørnestad, EØ | 1 |
| Olset, H | 1 |
| Dhar, I | 1 |
| Løland, K | 1 |
| Pedersen, EKR | 1 |
| Svingen, GFT | 1 |
| Svardal, A | 3 |
| Berge, RK | 4 |
| Ueland, PM | 1 |
| Tell, GS | 1 |
| Nilsen, DWT | 1 |
| Nordrehaug, JE | 1 |
| Nygaard, E | 1 |
| Nygård, O | 1 |
| Gencer, B | 2 |
| Li, XS | 2 |
| Gurmu, Y | 1 |
| Bonaca, MP | 1 |
| Morrow, DA | 1 |
| Cohen, M | 1 |
| Bhatt, DL | 1 |
| Steg, PG | 1 |
| Storey, RF | 1 |
| Johanson, P | 1 |
| Wang, Z | 3 |
| Hazen, SL | 3 |
| Sabatine, MS | 1 |
| Kolluru, GK | 1 |
| Kevil, CG | 1 |
| Haissman, JM | 2 |
| Haugaard, AK | 1 |
| Ostrowski, SR | 1 |
| Hov, JR | 1 |
| Trøseid, M | 3 |
| Nielsen, SD | 2 |
| Schiattarella, GG | 1 |
| Sannino, A | 1 |
| Toscano, E | 1 |
| Giugliano, G | 1 |
| Gargiulo, G | 1 |
| Franzone, A | 1 |
| Trimarco, B | 1 |
| Esposito, G | 1 |
| Perrino, C | 1 |
| Stubbs, JR | 1 |
| Stedman, MR | 1 |
| Liu, S | 1 |
| Long, J | 1 |
| Franchetti, Y | 1 |
| West, RE | 1 |
| Prokopienko, AJ | 1 |
| Mahnken, JD | 1 |
| Chertow, GM | 1 |
| Nolin, TD | 1 |
| Zhong, Z | 1 |
| Liu, J | 1 |
| Zhang, Q | 1 |
| Zhong, W | 1 |
| Li, B | 1 |
| Li, C | 1 |
| Liu, Z | 1 |
| Yang, M | 1 |
| Zhao, P | 1 |
| Sinha, A | 1 |
| Ma, Y | 1 |
| Scherzer, R | 1 |
| Rahalkar, S | 1 |
| Neilan, BD | 1 |
| Crane, H | 1 |
| Drozd, D | 1 |
| Martin, J | 1 |
| Deeks, SG | 1 |
| Hunt, P | 1 |
| Hsue, PY | 1 |
| Winther, SA | 1 |
| Øllgaard, JC | 1 |
| Tofte, N | 1 |
| Tarnow, L | 1 |
| Ahluwalia, TS | 1 |
| Jorsal, A | 1 |
| Theilade, S | 1 |
| Parving, HH | 1 |
| Hansen, TW | 1 |
| Pedersen, O | 1 |
| Rossing, P | 1 |
| Li, X | 1 |
| Sun, Y | 1 |
| Zhang, X | 1 |
| Wang, J | 1 |
| Yang, W | 1 |
| Zhang, S | 1 |
| Zhu, J | 1 |
| Jiang, H | 1 |
| Jia, D | 1 |
| Ou, T | 1 |
| Qi, Z | 1 |
| Qian, J | 1 |
| Sun, A | 1 |
| Ge, J | 1 |
| Knudsen, A | 1 |
| Hoel, H | 1 |
| Kjær, A | 1 |
| Kristoffersen, US | 1 |
| Katzenstein, TL | 1 |
| Ueland, T | 2 |
| Aukrust, P | 2 |
| Lebech, AM | 1 |
| Skagen, K | 1 |
| Holm, S | 1 |
| Abbas, A | 1 |
| Gregersen, I | 1 |
| Kummen, M | 1 |
| Bjerkeli, V | 1 |
| Reier-Nilsen, F | 1 |
| Russell, D | 1 |
| Karlsen, TH | 1 |
| Hov, JE | 1 |
| Halvorsen, B | 1 |
| Skjelland, M | 1 |
| Suzuki, T | 1 |
| Heaney, LM | 1 |
| Jones, DJ | 1 |
| Ng, LL | 1 |
| Obeid, S | 1 |
| Klingenberg, R | 1 |
| Mach, F | 1 |
| Räber, L | 1 |
| Windecker, S | 1 |
| Rodondi, N | 1 |
| Nanchen, D | 1 |
| Muller, O | 1 |
| Miranda, MX | 1 |
| Matter, CM | 1 |
| Wu, Y | 1 |
| Li, L | 1 |
| Alamri, HS | 1 |
| Gogonea, V | 1 |
| Chung, YM | 1 |
| Tang, WH | 1 |
| Lüscher, TF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| "Plant-Based Meat vs Animal Red Meat: a Randomized Cross-over Trial"[NCT04510324] | 41 participants (Actual) | Interventional | 2020-11-01 | Completed | |||
| Effects of a Whole Food Based Nutritional Formulation on Trimethylamine N-oxide and Cardiometabolic Endpoints in Healthy Adults.[NCT05795946] | 45 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
1 review available for trimethyloxamine and Myocardial Infarction
| Article | Year |
|---|---|
Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Dose-Response Relationship, Drug; Female; | 2017 |
19 other studies available for trimethyloxamine and Myocardial Infarction
| Article | Year |
|---|---|
Association between trimethylamine N-oxide and prognosis of patients with acute myocardial infarction and heart failure.
Topics: C-Reactive Protein; Heart Failure; Humans; Myocardial Infarction; Prognosis | 2022 |
Brown adipose tissue dysfunction promotes heart failure via a trimethylamine N-oxide-dependent mechanism.
Topics: Adipocytes, Brown; Adipose Tissue, Brown; Animals; Choline; Heart Failure; Methylamines; Mice; Myoca | 2022 |
Analysis of two intestinal bacterial metabolites (trimethylamine N-oxide and phenylacetylglutamine) in human serum samples of patients with T2DM and AMI using a liquid chromatography tandem mass spectrometry method.
Topics: Chromatography, Liquid; Diabetes Mellitus, Type 2; Glutamine; Humans; Isotopes; Methylamines; Myocar | 2022 |
Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxides; S | 2023 |
Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Follow-Up Studies; Heart Failure; Humans; Male; Methyla | 2020 |
Circulating trimethyllysine and risk of acute myocardial infarction in patients with suspected stable coronary heart disease.
Topics: Aged; Biomarkers; Coronary Disease; Female; Heart Disease Risk Factors; Humans; Lysine; Male; Methyl | 2020 |
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal | 2020 |
It's a "Gut Feeling": Association of Microbiota, Trimethylamine N-Oxide and Cardiovascular Outcomes.
Topics: Case-Control Studies; Gastrointestinal Microbiome; Humans; Methylamines; Microbiota; Myocardial Infa | 2020 |
Microbiota-dependent metabolite and cardiovascular disease marker trimethylamine-N-oxide (TMAO) is associated with monocyte activation but not platelet function in untreated HIV infection.
Topics: Adult; Betaine; Biomarkers; Blood Platelets; Cardiovascular Diseases; Carnitine; Choline; Cross-Sect | 2017 |
Trimethylamine
Topics: Adult; Aged; Angina, Unstable; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Hos | 2019 |
Targeted metabolomic analysis of plasma metabolites in patients with coronary heart disease in southern China.
Topics: Aged; Angina, Stable; Angina, Unstable; Biomarkers; Carnitine; China; Choline; Chromatography, Liqui | 2019 |
Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIV -Infected Adults.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atherosclerosis; Betaine; Carnitine; Carotid Artery Di | 2019 |
Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; Diabetic Nephropathies; Fema | 2019 |
Reductions in gut microbiota‑derived metabolite trimethylamine N‑oxide in the circulation may ameliorate myocardial infarction‑induced heart failure in rats, possibly by inhibiting interleukin‑8 secretion.
Topics: Animals; Gastrointestinal Microbiome; Heart Failure; Hexanols; Interleukin-8; Male; Methylamines; My | 2019 |
Gut microbe-derived metabolite trimethylamine N-oxide accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis.
Topics: Animals; Cell Differentiation; Collagen Type I; Disease Models, Animal; Fibroblasts; Fibrosis; Gastr | 2019 |
Microbiota-Dependent Marker TMAO Is Elevated in Silent Ischemia but Is Not Associated With First-Time Myocardial Infarction in HIV Infection.
Topics: Adolescent; Adult; Aged; Biomarkers; Case-Control Studies; Cohort Studies; Coronary Artery Disease; | 2016 |
The Carnitine-butyrobetaine-trimethylamine-N-oxide pathway and its association with cardiovascular mortality in patients with carotid atherosclerosis.
Topics: Aged; Betaine; Biomarkers; Carnitine; Carotid Stenosis; Case-Control Studies; Cause of Death; Chroma | 2016 |
Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Female; Humans; Male; Methylamines; Middle Aged; | 2017 |
Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors.
Topics: Acute Coronary Syndrome; Biomarkers; Cardiotonic Agents; Case-Control Studies; Female; Gastrointesti | 2017 |